Kayne Anderson Rudnick Investment Management’s Takeda Pharmaceutical TAK Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-21	Closed	-$325	–	1106
2025 Q2	$325	Hold	21	–	–	﹤0.01%	1027
2025 Q1	$312	Hold	21	–	–	﹤0.01%	926
2024 Q4	$278	Sell	21 -88	-81%	-$1.21K	﹤0.01%	963
2024 Q3	$1.55K	Sell	109 -585,734	-100%	-$8.31M	﹤0.01%	840
2024 Q2	$7.58M	Sell	585,843 -14,069	-2%	-$186K	0.02%	258
2024 Q1	$8.33M	Buy	599,912 +1,788	+0.3%	+$26K	0.02%	257
2023 Q4	$8.54M	Buy	598,124 +140,463	+31%	+$1.99M	0.02%	258
2023 Q3	$7.08M	Sell	457,661 -22,427	-5%	-$347K	0.02%	270
2023 Q2	$7.54M	Buy	480,088 +6,809	+1%	+$112K	0.02%	269
2023 Q1	$7.8M	Buy	+473,279	New	+$7.54M	0.02%	263
2022 Q2	–	Sell	-108	Closed	-$2K	–	680
2022 Q1	$2K	Buy	+108	New	+$1.59K	﹤0.01%	605

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's TAK Position: Q3 2025 in Review

Kayne Anderson Rudnick Investment Management sold out of Takeda Pharmaceutical (TAK) in Q3 2025, closing a stake of 21 shares — an estimated $325 sold.

Kayne Anderson Rudnick Investment Management first reported a position in TAK in Q1 2022 and held it in 11 quarters. The position peaked at $8.54M in Q4 2023. 330 funds tracked by Wall St. Rank hold TAK as of Q3 2025.

Kayne Anderson Rudnick Investment Management reported no remaining Takeda Pharmaceutical position as of Q3 2025 after selling out during the quarter.
Kayne Anderson Rudnick Investment Management sold 21 Takeda Pharmaceutical shares in Q3 2025, an estimated $325.
Kayne Anderson Rudnick Investment Management first reported a position in Takeda Pharmaceutical in Q1 2022 and held it in 11 quarters.
Kayne Anderson Rudnick Investment Management's Takeda Pharmaceutical position peaked at $8.54M in Q4 2023.
330 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2025.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.